Cargando…

Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients

BACKGROUND: Delineation of PSMA-positive tumor volume on PET using PSMA-ligands is of highest clinical interest as changes of PSMA-PET/CT-derived whole tumor volume (WTV) have shown to correlate with treatment response in metastatic prostate cancer patients. So far, WTV estimation was performed on P...

Descripción completa

Detalles Bibliográficos
Autores principales: Mittlmeier, Lena M., Brendel, Matthias, Beyer, Leonie, Albert, Nathalie L., Todica, Andrei, Zacherl, Mathias J., Wenter, Vera, Herlemann, Annika, Kretschmer, Alexander, Ledderose, Stephan T., Schmidt-Hegemann, Nina-Sophie, Kunz, Wolfgang G., Ricke, Jens, Bartenstein, Peter, Ilhan, Harun, Unterrainer, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176856/
https://www.ncbi.nlm.nih.gov/pubmed/34094956
http://dx.doi.org/10.3389/fonc.2021.663631
_version_ 1783703317024604160
author Mittlmeier, Lena M.
Brendel, Matthias
Beyer, Leonie
Albert, Nathalie L.
Todica, Andrei
Zacherl, Mathias J.
Wenter, Vera
Herlemann, Annika
Kretschmer, Alexander
Ledderose, Stephan T.
Schmidt-Hegemann, Nina-Sophie
Kunz, Wolfgang G.
Ricke, Jens
Bartenstein, Peter
Ilhan, Harun
Unterrainer, Marcus
author_facet Mittlmeier, Lena M.
Brendel, Matthias
Beyer, Leonie
Albert, Nathalie L.
Todica, Andrei
Zacherl, Mathias J.
Wenter, Vera
Herlemann, Annika
Kretschmer, Alexander
Ledderose, Stephan T.
Schmidt-Hegemann, Nina-Sophie
Kunz, Wolfgang G.
Ricke, Jens
Bartenstein, Peter
Ilhan, Harun
Unterrainer, Marcus
author_sort Mittlmeier, Lena M.
collection PubMed
description BACKGROUND: Delineation of PSMA-positive tumor volume on PET using PSMA-ligands is of highest clinical interest as changes of PSMA-PET/CT-derived whole tumor volume (WTV) have shown to correlate with treatment response in metastatic prostate cancer patients. So far, WTV estimation was performed on PET using (68)Ga-labeled ligands; nonetheless, (18)F-labeled PET ligands are gaining increasing importance due to advantages over (68)Ga-labeled compounds. However, standardized tumor delineation methods for (18)F-labeled PET ligands have not been established so far. As correlation of PET-based information and morphological extent in osseous and visceral metastases is hampered by morphological delineation, low contrast in liver tissue and movement artefacts, we correlated CT-based volume of lymph node metastases (LNM) and different PET-based delineation approaches for thresholding on (18)F-PSMA-1007 PET. METHODS: Fifty patients with metastatic prostate cancer, (18)F-PSMA-1007 PET/CT and non-bulky LNM (short-axis diameter ≥10mm) were included. Fifty LNM were volumetrically assessed on contrast-enhanced CT (volumetric reference standard). Different approaches for tumor volume delineation were applied and correlated with the reference standard: I) fixed SUV threshold, II) isocontour thresholding relative to SUV(max) (SUV%), and thresholds relative to III) liver (SUV(liver)), IV) parotis (SUV(parotis)) and V) spleen (SUV(spleen)). RESULTS: A fixed SUV of 4.0 (r=0.807, r(2) = 0.651, p<0.001) showed the best overall association with the volumetric reference. 55% SUV(max) (r=0.627, r(2) = 0.393, p<0.001) showed highest association using an isocontour-based threshold. Best background-based approaches were 60% SUV(liver) (r=0.715, r(2) = 0.511, p<0.001), 80% SUV(parotis) (r=0.762, r(2) = 0.581, p<0.001) and 60% SUV(spleen) (r=0.645, r(2) = 0.416, p<0.001). Background tissues SUV(liver,) SUV(parotis) & SUV(spleen) did not correlate (p>0.05 each). Recently reported cut-offs for intraprostatic tumor delineation (isocontour 44% SUV(max), 42% SUV(max) and 20% SUV(max)) revealed inferior association for LNM delineation. CONCLUSIONS: A threshold of SUV 4.0 for tumor delineation showed highest association with volumetric reference standard irrespective of potential changes in PSMA-avidity of background tissues (e. g. parotis). This approach is easily applicable in clinical routine without specific software requirements. Further studies applying this approach for total tumor volume delineation are initiated.
format Online
Article
Text
id pubmed-8176856
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81768562021-06-05 Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients Mittlmeier, Lena M. Brendel, Matthias Beyer, Leonie Albert, Nathalie L. Todica, Andrei Zacherl, Mathias J. Wenter, Vera Herlemann, Annika Kretschmer, Alexander Ledderose, Stephan T. Schmidt-Hegemann, Nina-Sophie Kunz, Wolfgang G. Ricke, Jens Bartenstein, Peter Ilhan, Harun Unterrainer, Marcus Front Oncol Oncology BACKGROUND: Delineation of PSMA-positive tumor volume on PET using PSMA-ligands is of highest clinical interest as changes of PSMA-PET/CT-derived whole tumor volume (WTV) have shown to correlate with treatment response in metastatic prostate cancer patients. So far, WTV estimation was performed on PET using (68)Ga-labeled ligands; nonetheless, (18)F-labeled PET ligands are gaining increasing importance due to advantages over (68)Ga-labeled compounds. However, standardized tumor delineation methods for (18)F-labeled PET ligands have not been established so far. As correlation of PET-based information and morphological extent in osseous and visceral metastases is hampered by morphological delineation, low contrast in liver tissue and movement artefacts, we correlated CT-based volume of lymph node metastases (LNM) and different PET-based delineation approaches for thresholding on (18)F-PSMA-1007 PET. METHODS: Fifty patients with metastatic prostate cancer, (18)F-PSMA-1007 PET/CT and non-bulky LNM (short-axis diameter ≥10mm) were included. Fifty LNM were volumetrically assessed on contrast-enhanced CT (volumetric reference standard). Different approaches for tumor volume delineation were applied and correlated with the reference standard: I) fixed SUV threshold, II) isocontour thresholding relative to SUV(max) (SUV%), and thresholds relative to III) liver (SUV(liver)), IV) parotis (SUV(parotis)) and V) spleen (SUV(spleen)). RESULTS: A fixed SUV of 4.0 (r=0.807, r(2) = 0.651, p<0.001) showed the best overall association with the volumetric reference. 55% SUV(max) (r=0.627, r(2) = 0.393, p<0.001) showed highest association using an isocontour-based threshold. Best background-based approaches were 60% SUV(liver) (r=0.715, r(2) = 0.511, p<0.001), 80% SUV(parotis) (r=0.762, r(2) = 0.581, p<0.001) and 60% SUV(spleen) (r=0.645, r(2) = 0.416, p<0.001). Background tissues SUV(liver,) SUV(parotis) & SUV(spleen) did not correlate (p>0.05 each). Recently reported cut-offs for intraprostatic tumor delineation (isocontour 44% SUV(max), 42% SUV(max) and 20% SUV(max)) revealed inferior association for LNM delineation. CONCLUSIONS: A threshold of SUV 4.0 for tumor delineation showed highest association with volumetric reference standard irrespective of potential changes in PSMA-avidity of background tissues (e. g. parotis). This approach is easily applicable in clinical routine without specific software requirements. Further studies applying this approach for total tumor volume delineation are initiated. Frontiers Media S.A. 2021-05-21 /pmc/articles/PMC8176856/ /pubmed/34094956 http://dx.doi.org/10.3389/fonc.2021.663631 Text en Copyright © 2021 Mittlmeier, Brendel, Beyer, Albert, Todica, Zacherl, Wenter, Herlemann, Kretschmer, Ledderose, Schmidt-Hegemann, Kunz, Ricke, Bartenstein, Ilhan and Unterrainer https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Mittlmeier, Lena M.
Brendel, Matthias
Beyer, Leonie
Albert, Nathalie L.
Todica, Andrei
Zacherl, Mathias J.
Wenter, Vera
Herlemann, Annika
Kretschmer, Alexander
Ledderose, Stephan T.
Schmidt-Hegemann, Nina-Sophie
Kunz, Wolfgang G.
Ricke, Jens
Bartenstein, Peter
Ilhan, Harun
Unterrainer, Marcus
Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
title Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
title_full Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
title_fullStr Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
title_full_unstemmed Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
title_short Feasibility of Different Tumor Delineation Approaches for (18)F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
title_sort feasibility of different tumor delineation approaches for (18)f-psma-1007 pet/ct imaging in prostate cancer patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176856/
https://www.ncbi.nlm.nih.gov/pubmed/34094956
http://dx.doi.org/10.3389/fonc.2021.663631
work_keys_str_mv AT mittlmeierlenam feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients
AT brendelmatthias feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients
AT beyerleonie feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients
AT albertnathaliel feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients
AT todicaandrei feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients
AT zacherlmathiasj feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients
AT wentervera feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients
AT herlemannannika feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients
AT kretschmeralexander feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients
AT ledderosestephant feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients
AT schmidthegemannninasophie feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients
AT kunzwolfgangg feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients
AT rickejens feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients
AT bartensteinpeter feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients
AT ilhanharun feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients
AT unterrainermarcus feasibilityofdifferenttumordelineationapproachesfor18fpsma1007petctimaginginprostatecancerpatients